Conformis, Inc. (CFMS)
| Market Cap | 154.50M |
| Revenue (ttm) | 68.76M |
| Net Income (ttm) | -24.29M |
| Shares Out | 182.43M |
| EPS (ttm) | -0.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $0.847 |
| Previous Close | $0.829 |
| Change ($) | 0.018 |
| Change (%) | 2.16% |
| Day's Open | 0.820 |
| Day's Range | 0.810 - 0.860 |
| Day's Volume | 2,583,206 |
| 52-Week Range | 0.602 - 1.490 |
BILLERICA, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will release its financial results for the first quarter ended March 31, 2021 after the market...
Independent, retrospective review of 2016-2019 surgeon data by University of Washington researchers demonstrates that Conformis iTotal® knee replacement implants enable expedited surgical time and reduc...
Independent, retrospective review of 2016-2019 surgeon data by University of Washington researchers demonstrates that Conformis iTotal® knee replacement implants enable expedited surgical time and reduc...
ConforMIS (CFMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ConforMIS (CFMS) delivered earnings and revenue surprises of 27.27% and -0.08%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
BILLERICA, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today financial results for the fourth quarter and year ended December 31, 2020.
Shares of ConforMIS (NASDAQ: CFMS) traded up as high as 37% in Tuesday's pre-market trading session. The company released a press release stating that the Therapeutic Goods Administration, part of the A...
On Wednesday, March 03, Conformis (NASDAQ:CFMS) will release its latest earnings report. Decipher the announcement with Benzinga's help.
CFMS stock is jumping as Conformis preps to introduce a knee replacement system in Australia. Here's what you should know.
The iTotal® PS total knee replacement system is designed so that its patient-specific implants fit the unique size and shape of each patient's knee, and provide optimal stability throughout the full ran...
BILLERICA, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (Nasdaq: CFMS) today announced it has priced an underwritten public offering of 80,952,381 shares of its common stock at an offering p...
BILLERICA, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (Nasdaq: CFMS) today announced that it intends to offer shares of its common stock in an underwritten public offering. Conformis inten...
BILLERICA, Mass. and COLUMBIA CITY, Ind., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) and SITES Medical, a firm dedicated to inventing and de-risking new orthopedic medical device te...
Conformis (CFMS) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
BILLERICA, Mass., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leader in patient-specific knee and hip instrumentation and implants, announced today that Mark Augusti, Chief Execu...
Cordera™ Match Hip System combines the proven Cordera™ hip stem with Conformis' state-of-the-art, personalized pre-operative plans and patient-specific instruments. Cordera™ Match Hip System combines th...
BILLERICA, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Mark Augusti, President and Chief Executive Officer, and Robert Howe, Chief Financial Officer, will...
BILLERICA, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that the Company has appointed Bart Lagae as its new VP, International Sales & Marketing.
Conformis's (CFMS) CEO Mark Augusti on Q3 2020 Results - Earnings Call Transcript
ConforMIS (CFMS) delivered earnings and revenue surprises of 25.00% and 0.13%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
BILLERICA, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today financial results for the third quarter ended September 30, 2020.
Conformis (NASDAQ: CFMS) releases its next round of earnings this Wednesday, November 04. Get the latest predictions in Benzinga's essential guide to the company's Q3 earnings report.
BILLERICA, Mass., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Mark Augusti, President and Chief Executive Officer, and Robert Howe, Chief Financial Officer, will...
ConforMIS (CFMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Call to be Hosted on November 4, 2020 Earnings Call to be Hosted on November 4, 2020
Cordera™ Hip System with optional patient-specific instrumentation and personalized surgical plan joins the 3D Conformis Hip System as the latest hip technology from Conformis Cordera™ Hip System with o...
BILLERICA, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (Nasdaq: CFMS) today announced it has entered into a definitive agreement with a healthcare focused institutional investor to sell ...
BILLERICA, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) will participate in the 2020 Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held September 21-23, 2...
BILLERICA, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) will participate in the upcoming 2020 H.C. Wainwright 22nd Annual Global Investment Conference, to be held virtually ...
BILLERICA, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Mark Augusti, President and Chief Executive Officer, and members of the Company’s executive mana...
BILLERICA, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it completed the second of three milestones pursuant to the License Agreement and Development Agr...
BILLERICA, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that the Company has appointed Farzin Khaghani as its new VP, US Marketing.
Clinical research published online in July 2020 in The Journal of Bone and Joint Surgery Reviews found that the patients studied, who all received Conformis patient-specific iTotal PS (posterior-stabili...
ConforMIS (CFMS) delivered earnings and revenue surprises of 76.92% and 32.93%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Conformis' (CFMS) CEO Mark Augusti on Q2 2020 Results - Earnings Call Transcript
BILLERICA, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today financial results for the second quarter ended June 30, 2020.
BILLERICA, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that management will present at the Canaccord Genuity 40th Annual Growth Conference. The event is bein...
ConforMIS (CFMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Call to be Hosted on August 5, 2020
Conformis' (CFMS) latest iTotal Identity PS Knee System clears FDA hurdle, paving the way for providing better patient-specific pre-operative surgical plans.
iTotal® Identity PS joins iTotal® Identity CR as the latest personalized knee technology from Conformis iTotal® Identity PS joins iTotal® Identity CR as the latest personalized knee technology from Conf...
Conformis and Zimmer Biomet settled disputes related to Patient-Specific Instrument Patents for Use with Off-the-Shelf Knee, Hip, and Shoulder Implants Conformis and Zimmer Biomet settled disputes relat...
Dr. Malte Asseln awarded annual prize by German Society for Biomedical Engineering at the VDE Association and the Klee Family Foundation for his scientific computer-and-image-based workflow to optimize ...
Conformis (CFMS) CEO Mark Augusti on Q1 2020 Results - Earnings Call Transcript
ConforMIS (CFMS) delivered earnings and revenue surprises of -55.56% and -13.04%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
ConforMIS (CFMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BILLERICA, Mass., April 20, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) today announced that on April 17, 2020 the Company entered into a $4,719,800 promissory note with East West Bank (NAS...
Withdraws Previous 2020 Growth Outlook
Inside the top-ranked stocks that have been exhibiting rising P/E ratios.
Conformis, Inc. (CFMS) CEO Mark Augusti on Q4 2019 Results - Earnings Call Transcript
About CFMS
Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers personalized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a personalized bicompartmental knee replacement system; iUni, a personalized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee; and iTotal Identity, a knee system. It also provides Conformis Hip System and Cordera h... [Read more...]
| Industry Medical Devices | IPO Date Jul 1, 2015 |
| Stock Exchange NASDAQ | Ticker Symbol CFMS |
Financial Performance
In 2020, Conformis's revenue was $68.76 million, a decrease of -11.19% compared to the previous year's $77.43 million. Losses were -$24.29 million, -14.70% less than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for Conformis stock is "Buy." The 12-month stock price forecast is 2.33, which is an increase of 175.12% from the latest price.